<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">32547252</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1179-142X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>International medical case reports journal</Title>
          <ISOAbbreviation>Int Med Case Rep J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bickerstaff's Brainstem Encephalitis Suspected as Functional Neurologic Disorders.</ArticleTitle>
        <Pagination>
          <StartPage>177</StartPage>
          <EndPage>181</EndPage>
          <MedlinePgn>177-181</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/IMCRJ.S249818</ELocationID>
        <Abstract>
          <AbstractText>Functional neurologic disorders feature nervous system symptoms that cannot be explained by a neurological disease or other medical condition. The patient described here was a 21-year-old Japanese woman who was initially diagnosed with a functional neurologic disorder based on numbness and weakness of the limbs with no abnormalities in routine examinations. Further detailed examinations revealed monocytes in cerebrospinal fluid (CSF), and electroencephalography revealed widespread, low-voltage, slow waves with concentrated spindle waves. Thus, encephalitis was suspected, and steroid pulse therapy was initiated. Her symptoms subsequently improved. Afterward, CSF analysis was positive for serum anti-GQ1b IgG antibodies. We made a final diagnosis of Bickerstaff's brainstem encephalitis (BBE). Our report describes the difficult differentiation of functional neurologic disorders from BBE. Physicians and psychiatrists should be aware of BBE.</AbstractText>
          <CopyrightInformation>© 2020 Okayasu et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Okayasu</LastName>
            <ForeName>Hiroaki</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-4206-307X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Dokkyo Medical University, Tochigi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yasui-Furukori</LastName>
            <ForeName>Norio</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Dokkyo Medical University, Tochigi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kadowaki</LastName>
            <ForeName>Taro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Dokkyo Medical University, Tochigi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Funakoshi</LastName>
            <ForeName>Kei</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Dokkyo Medical University, Tochigi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirata</LastName>
            <ForeName>Koichi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Dokkyo Medical University, Tochigi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimoda</LastName>
            <ForeName>Kazutaka</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Dokkyo Medical University, Tochigi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int Med Case Rep J</MedlineTA>
        <NlmUniqueID>101566269</NlmUniqueID>
        <ISSNLinking>1179-142X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bickerstaff’s brainstem encephalitis</Keyword>
        <Keyword MajorTopicYN="N">Guillain-Barré syndrome</Keyword>
        <Keyword MajorTopicYN="N">Miller Fisher syndrome</Keyword>
        <Keyword MajorTopicYN="N">consciousness disturbance</Keyword>
        <Keyword MajorTopicYN="N">functional neurologic disorder</Keyword>
      </KeywordList>
      <CoiStatement>Kazutaka Shimoda has received research support from Novartis Pharma K.K., Dainippon Sumitomo Pharma Co., Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., Eisai Co., Ltd., Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., and Takeda Pharmaceutical Co., Ltd. and has received honoraria from Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Janssen Pharmaceutical K.K., Shionogi &amp; Co., Ltd., Dainippon Sumitomo Pharma Co., Daiichi Sankyo Co., and Pfizer Inc. Koichi Hirata has received research support from Otsuka Pharmaceutical Co., Takeda Pharmaceutical Co., Novartis Pharma, AbbVie Pharmaceutical Co., MSD Pharmaceutical Co., Esai Pharmaceutical Co., Pfizer Pharmaceutical Co., Kyowa Hakko-Kirin Pharmaceutical Co. and Asteras Pharmaceutical Co. Norio Yasui-Furukori has received research support from Otsuka Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharmaceutical Co., and MSD Co. The funders did not have any role in data collection or in the study design, analysis, decision to publish, or preparation of the manuscript. The remaining authors declare that they have no competing interests to report.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32547252</ArticleId>
        <ArticleId IdType="pmc">PMC7244345</ArticleId>
        <ArticleId IdType="doi">10.2147/IMCRJ.S249818</ArticleId>
        <ArticleId IdType="pii">249818</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Carson A, Hallett M, Stone J. Assessment of patients with functional neurologic disorders. Handb Clin Neurol. 2016;139:169–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27719837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards MJ. Neurobiologic theories of functional neurologic disorders. Handb Clin Neurol. 2017;139:131–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27719834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ewald H, Rogne T, Ewald K, et al. Somatization in patients newly admitted to a neurology department. Acta Psychiatr Scand. 1994;89:174–179. doi:10.1111/j.1600-0447.1994.tb08088.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0447.1994.tb08088.x</ArticleId>
            <ArticleId IdType="pubmed">8178675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma V, Chan YC, Ong THL, Wilder-Smith EP. Bickerstaff’s brainstem encephalitis: can it recur?
J Clin Neurosci. 2006;13:277–279. doi:10.1016/j.jocn.2005.01.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2005.01.011</ArticleId>
            <ArticleId IdType="pubmed">16442797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N, Tagawa Y, Irie F, et al. Close association of Guillain–Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1a. J Neuroimmunol. 1997;74:30–34. doi:10.1016/S0165-5728(96)00201-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(96)00201-9</ArticleId>
            <ArticleId IdType="pubmed">9119976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagawa Y, Yuki N, Hirata K. High anti-GM1 and anti-GD1a IgG antibody titers are detected in Guillain–Barré syndrome but not in chronic inflammatory demyelinating polyneuropathy. Eur Neurol. 2002;48:118–119. doi:10.1159/000062988</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000062988</ArticleId>
            <ArticleId IdType="pubmed">12187004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff’s brain stem encephalitis and Fisher’s syndrome. J Neurol Sci. 1993;118:83–87. doi:10.1016/0022-510X(93)90250-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-510X(93)90250-3</ArticleId>
            <ArticleId IdType="pubmed">8229054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba A, Takashima M, Hamaguchi M, et al.
Phosphate metabolism during muscular contraction in starved frogs (Rana catesbeiana). Comp Biochem Physiol Comp Physiol. 1993;106:725–729. doi:10.1016/0300-9629(93)90388-K</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0300-9629(93)90388-K</ArticleId>
            <ArticleId IdType="pubmed">7906630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N, Sato S, Tsuji S, et al. Frequent presence of anti-GQ1b antibody in Fisher’s syndrome. Neurology. 1993;43:414–417. doi:10.1212/WNL.43.2.414</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.43.2.414</ArticleId>
            <ArticleId IdType="pubmed">8437711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N. Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody. Ann Neurol. 1996;3:668–672. doi:10.1002/ana.410390517</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410390517</ArticleId>
            <ArticleId IdType="pubmed">8619553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawara K, Kuwabara S, Yuki N. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle Nerve. 2002;26:845–849. doi:10.1002/mus.10246</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.10246</ArticleId>
            <ArticleId IdType="pubmed">12451613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michev A, Musso P, Foiadelli T, et al. Bickerstaff Brainstem Encephalitis and overlapping Guillain-Barré syndrome in children: report of two cases and review of the literature. Eur J Paediatr Neurol. 2019;23(1):43–52. doi:10.1016/j.ejpn.2018.11.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpn.2018.11.008</ArticleId>
            <ArticleId IdType="pubmed">30502045</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
